January 9, 2013- Vivus (VVUS) has received some very good news regarding sales of its primary product, a drug called Osymia that fights obesity.
The company, which relies heavily on strong sales for Osymia, got exactly what it wanted, a huge increase in sales for the month that ended December 21st.
In truth, sales jumped by an impressive sixty eight percent over the previous four weeks while the company’s stock was noticed by bullish investors. It increased in value by a very significant nine percent to $15.02 in premarket trading. It will be interesting to track the stock’s performance after the trading day ends to see how well it performed.
A spokesman for Vivus issued a public announcement that indicated sales of the obesity drug resulted in the shipment of 12,978 prescriptions in December, up from 7,749 prescriptions shipped in the previous four weeks dating back to November.
New prescriptions reached a total of 5,229 shipments made around the country, a figure that was well above what an analyst’s forecast which amounted to 1,327 new prescriptions.
The same analyst predicted that the company will be able to enjoy one billion dollars in sales for Osymia by 2019.